Cheryl Gault Sells 2,014 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock

Rapport Therapeutics, Inc. (NASDAQ:RAPP) COO Cheryl Gault sold 2,014 shares of Rapport Therapeutics stock in a transaction on Thursday, March 5th. The shares were sold at an average price of $28.93, for a total value of $58,265.02. Following the completion of the transaction, the chief operating officer owned 169,914 shares in the company, valued at $4,915,612.02. The trade was a 1.17% decrease in their position. The sale was disclosed in a legal filing with the SEC, which can be accessed through the SEC website.

Rapport Therapeutics Trading Down 3.0%

RAPP stock opened at $29.63 on Wednesday. The company has a market cap of $1.41 billion, a PE ratio of -10.93 and a beta of 1.51. The stock has a 50-day moving average price of $28.14 and a two-hundred day moving average price of $26.86. Rapport Therapeutics, Inc. has a 12-month low of $7.73 and a 12-month high of $42.27.

Rapport Therapeutics (NASDAQ:RAPP) last released its quarterly earnings data on Tuesday, March 10th. The company reported ($0.72) EPS for the quarter, missing analysts’ consensus estimates of ($0.65) by ($0.07). Equities analysts forecast that Rapport Therapeutics, Inc. will post -3.65 EPS for the current fiscal year.

Hedge Funds Weigh In On Rapport Therapeutics

A number of institutional investors have recently added to or reduced their stakes in RAPP. Strs Ohio boosted its position in Rapport Therapeutics by 23.5% in the 3rd quarter. Strs Ohio now owns 2,100 shares of the company’s stock valued at $62,000 after buying an additional 400 shares during the last quarter. Russell Investments Group Ltd. increased its position in shares of Rapport Therapeutics by 56.9% during the fourth quarter. Russell Investments Group Ltd. now owns 2,282 shares of the company’s stock worth $69,000 after acquiring an additional 828 shares during the last quarter. Mirae Asset Global Investments Co. Ltd. lifted its stake in shares of Rapport Therapeutics by 64.1% in the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,316 shares of the company’s stock worth $70,000 after acquiring an additional 905 shares in the last quarter. Meeder Asset Management Inc. acquired a new position in shares of Rapport Therapeutics in the fourth quarter worth about $37,000. Finally, Creative Planning boosted its holdings in Rapport Therapeutics by 12.8% in the third quarter. Creative Planning now owns 11,959 shares of the company’s stock valued at $355,000 after purchasing an additional 1,357 shares during the last quarter.

Key Headlines Impacting Rapport Therapeutics

Here are the key news stories impacting Rapport Therapeutics this week:

• Positive Sentiment: Phase‑2a efficacy and Phase‑3 timing — RAP‑219 showed robust, consistent activity in patients with focal‑onset seizures in a Phase 2a trial and Rapport expects to initiate a Phase‑3 program in Q2 2026; the program was also expanded into primary generalized tonic‑clonic seizures and bipolar mania based on the data. GlobeNewswire: Financial Results & Business Update
• Positive Sentiment: China deal provides non‑dilutive cash and upside — Rapport granted Tenacia exclusive Greater China rights to RAP‑219 and will receive $20M upfront, up to $308M in development/commercial milestones and tiered royalties, accelerating regional development and de‑risking part of the program. FierceBiotech: Tenacia deal
• Positive Sentiment: Strong cash runway — Rapport ended 2025 with $490.5M in cash, equivalents and short‑term investments, which management says should fund operations into H2 2029, reducing near‑term financing risk. GlobeNewswire: Financial Results & Business Update
• Neutral Sentiment: Insider sale — COO Cheryl Gault sold 2,014 shares (~$58k) on March 5; the sale is small relative to her remaining holdings and may reflect diversification rather than negative company news. SEC filing / MarketBeat: Insider sale
• Negative Sentiment: Quarterly EPS miss — Rapport reported Q4 EPS of ($0.72), missing consensus of ($0.65) by $0.07, which likely pressured the stock despite reassuring commentary on cash and pipeline progress. Quarterly press release (Quartr)

Analyst Ratings Changes

A number of research analysts have weighed in on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Rapport Therapeutics in a research report on Thursday, January 22nd. The Goldman Sachs Group reissued a “buy” rating on shares of Rapport Therapeutics in a research report on Friday, December 19th. HC Wainwright lifted their target price on shares of Rapport Therapeutics from $34.00 to $40.00 and gave the company a “buy” rating in a report on Tuesday, December 9th. Wells Fargo & Company assumed coverage on shares of Rapport Therapeutics in a research report on Monday, February 2nd. They set an “overweight” rating and a $43.00 price target for the company. Finally, Wall Street Zen upgraded Rapport Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, February 28th. Eight investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $50.80.

Rapport Therapeutics Company Profile

Rapport Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted therapies for patients with cancer. The company leverages a proprietary discovery engine to identify novel tumor-associated antigens and develop tailored biologic and small-molecule candidates designed to modulate key oncogenic pathways. With a pipeline comprising multiple preclinical and early clinical assets, Rapport is committed to advancing precision medicine approaches and addressing unmet needs in oncology.

Rapport’s discovery engine combines high-throughput screening, molecular profiling and in vivo validation to accelerate the progression of lead candidates from the laboratory to clinical evaluation.